MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales
Ticker: MGRX · Form: 8-K · Filed: Dec 26, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Dec 26, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001, $250,000, $2.71, $100,000, $2.57 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
MANGOCEUTICALS, INC. signed a big deal and sold some stock on Dec 18th. 8-K filed Dec 26th.
AI Summary
On December 18, 2024, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on December 26, 2024.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- December 18, 2024 (date) — Date of Earliest Event Reported
- December 26, 2024 (date) — Filing Date
- 15110 N. Dallas Parkway , Suite 600 Dallas , Texas 75248 (address) — Principal executive offices
- (214) 242-9619 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by MANGOCEUTICALS, INC. on December 18, 2024?
The filing states that MANGOCEUTICALS, INC. entered into a material definitive agreement on December 18, 2024, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by MANGOCEUTICALS, INC.?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not detailed in the provided text.
When was the 8-K report filed with the SEC?
The 8-K report was filed on December 26, 2024.
What is the principal executive office address for MANGOCEUTICALS, INC.?
The principal executive office address is 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What is the SEC file number for MANGOCEUTICALS, INC.?
The SEC file number for MANGOCEUTICALS, INC. is 001-41615.
Filing Stats: 2,051 words · 8 min read · ~7 pages · Grade level 14.4 · Accepted 2024-12-26 16:30:26
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $250,000 — pany (" Series B Preferred Stock ") for $250,000, and warrants to purchase 330,000 share
- $2.71 — nt Shares "), with an exercise price of $2.71 per share, and 100 shares of Series B P
- $100,000 — shares of Series B Preferred Stock for $100,000, and Warrants to purchase 132,000 share
- $2.57 — common stock with an exercise price of $2.57 per share, respectively. The Company
- $900,000 — anticipates selling up to an additional $900,000 of shares of Series B Preferred Stock a
- $2.25 — lder thereof, based on a Floor Price of $2.25 per share. If the Warrants issued to
Filing Documents
- form8-k.htm (8-K) — 61KB
- ex4-1.htm (EX-4.1) — 93KB
- ex10-1.htm (EX-10.1) — 226KB
- 0001493152-24-052111.txt ( ) — 636KB
- mgrx-20241218.xsd (EX-101.SCH) — 3KB
- mgrx-20241218_lab.xml (EX-101.LAB) — 33KB
- mgrx-20241218_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: December 26, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer